YOUR BUSINESS AUTHORITY
Springfield, MO
Johnson & Johnson's COVID-19 vaccine added $502 million to its third-quarter revenue.
Revenue during the quarter was $23.3 billion, short of the $23.7 billion expected by analysts.
Adjusted earnings per share came to $2.60, beating the $2.35 per share estimate.
Read more from CNBC.
Downtown problems partly a product of perception, officials say.